Profit and FCF down as they are investing in sales/marketing + product development this was well flagged in previous announcements...
Would be nice to see more US growth - not having the success there that they have elsewhere. Intuit a tougher competitor than MYOB
- Forums
- ASX - By Stock
- XRO
- Ann: Interim Report & Appendix 4D H1 FY22
Ann: Interim Report & Appendix 4D H1 FY22, page-10
-
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add XRO (ASX) to my watchlist
(20min delay)
|
|||||
Last
$161.69 |
Change
0.550(0.34%) |
Mkt cap ! $24.65B |
Open | High | Low | Value | Volume |
$161.07 | $162.31 | $160.39 | $24.17M | 149.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 47 | $161.67 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$161.69 | 11 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 46 | 161.570 |
4 | 33 | 161.550 |
2 | 35 | 161.540 |
7 | 123 | 161.520 |
1 | 25 | 161.500 |
Price($) | Vol. | No. |
---|---|---|
161.610 | 83 | 7 |
161.620 | 9 | 1 |
161.630 | 15 | 2 |
161.640 | 108 | 6 |
161.650 | 44 | 7 |
Last trade - 14.24pm 13/11/2024 (20 minute delay) ? |
Featured News
XRO (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online